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Abstract
Small- colony variants (SCVs) are commonly observed in evolution experiments and 
clinical isolates, being associated with antibiotic resistance and persistent infections. 
We recently observed the repeated emergence of Escherichia coli SCVs during 
adaptation to the interaction with macrophages. To identify the genetic targets 
underlying the emergence of this clinically relevant morphotype, we performed 
whole- genome sequencing of independently evolved SCV clones. We uncovered 
novel mutational targets, not previously associated with SCVs (e.g. cydA, pepP) 
and observed widespread functional parallelism. All SCV clones had mutations in 
genes related to the electron- transport chain. As SCVs emerged during adaptation 
to macrophages, and often show increased antibiotic resistance, we measured SCV 
fitness inside macrophages and measured their antibiotic resistance profiles. SCVs 
had a fitness advantage inside macrophages and showed increased aminoglycoside 
resistance in vitro, but had collateral sensitivity to other antibiotics (e.g. tetracy-
cline). Importantly, we observed similar results in vivo. SCVs had a fitness advantage 
upon colonization of the mouse gut, which could be tuned by antibiotic treatment: 
kanamycin (aminoglycoside) increased SCV fitness, but tetracycline strongly reduced 
it. Our results highlight the power of using experimental evolution as the basis 
for identifying the causes and consequences of adaptation during host- microbe 
interactions.
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O R I G I N A L  A R T I C L E
Macrophage adaptation leads to parallel evolution of 
genetically diverse Escherichia coli small- colony variants with 
increased fitness in vivo and antibiotic collateral sensitivity
Ricardo S. Ramiro | Henrique Costa | Isabel Gordo
1  | INTRODUCTION
Variation in colony morphology is often observed during in vitro bac-
terial adaptation (Miskinyte et al., 2013; Rainey & Travisano, 1998; 
Rozen & Lenski, 2000; Traverse, Mayo- Smith, Poltak, & Cooper, 2013). 
One of the most commonly observed morphotypes are small- colony 
variants (SCVs) (e.g. Miskinyte et al., 2013; Rozen & Lenski, 2000; 
Traverse et al., 2013). SCVs emerge in response to multiple selective 
pressures, including adaptation to: single (Rozen & Lenski, 2000) or 
multiple carbon sources (Friesen, Saxer, Travisano, & Doebeli, 2004), 
biofilm conditions (Penterman et al., 2014; Traverse et al., 2013), the 
mouse gut (Lee et al., 2010), antibiotics (Musher, Baughn, Temple-
ton, & Minuth, 1977; Yegian, Gallo, & Toll, 1959), antimicrobial pep-
tides (Pranting & Andersson, 2010) or the intracellular environment 
of nonprofessional phagocytes (Cano, Pucciarelli, Martínez- Moya, 
Casadesús, & García- del Portillo, 2003; Tuchscherr et al., 2011; Vesga 
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et al., 1996). As could be expected, from such a diverse set of selective 
pressures, SCVs also present a diverse genetic basis (Cooper, Staples, 
Traverse, & Ellis, 2014; Herron & Doebeli, 2013; Pranting & Anders-
son, 2010; Proctor et al., 2006). The most common mutations are in 
genes related to the electron- transport chain (ETC), which are known 
to lead to the SCV phenotype in many species, both Gram- negative 
and Gram- positive (Cano et al., 2003; Dean, Olsen, Long, Rosato, & 
Musser, 2014; Kastbjerg, Hein- Kristensen, & Gram, 2014; Roggen-
kamp et al., 1998). Importantly, SCVs have been widely associated 
with antibiotic resistance, and for some of these species (e.g. S. aureus, 
E. coli, Pseudomonas aeruginosa), SCVs have been associated with 
chronic infections, such as infections of the lungs of cystic- fibrosis 
patients, urinary tract or prosthesis- associated infections (Häussler, 
Tümmler, Weißbrodt, Rohde, & Steinmetz, 1999; Proctor, van Lan-
gevelde, Kristjansson, Maslow, & Arbeit, 1995; Proctor et al., 2006; 
Roggenkamp et al., 1998; Rusthoven, Davies, & Lerner, 1979). In these 
natural infections, disentangling which selective pressures lead to par-
ticular phenotypes is often difficult. Interestingly, some of these SCVs 
show similar genetic/phenotypic bases to those which arise during 
evolution experiments (McDonald, Gehrig, Meintjes, Zhang, & Rainey, 
2009; Proctor et al., 1995; Smith et al., 2006; Vesga et al., 1996), sug-
gesting that experimental evolution may be useful to identify import-
ant selective pressures in vivo.
A recent aim in evolutionary biology is to understand whether evo-
lution experiments can help understanding natural variation. A way to 
do this is to incorporate the selective pressures which are thought to 
be important in nature into evolution experiments (Bailey & Batail-
lon, 2016). In the context of infections and at the commensal–patho-
gen transition, a major selective pressure is the innate immune sys-
tem, with macrophages (MΦs) being key in the response to microbial 
infections (Wynn, Chawla, & Pollard, 2013). Due to this role of MΦs, 
several studies have recently used experimental adaptation to under-
stand how yeast or bacteria evolve under MΦ attack (Azevedo et al., 
2016; Ensminger, Yassin, Miron, & Isberg, 2012; Miskinyte et al., 2013; 
Vázquez et al., 2014; Wartenberg et al., 2014). Recently, we used this 
approach to study the adaptation of a commensal E. coli to the inter-
action with MΦs (Miskinyte et al., 2013). In this experiment, replicate 
bacterial populations were allowed to evolve for 30 days in the pres-
ence of MΦs, while inhabiting both intracellular and extracellular envi-
ronments (see Appendix S1 for summary of this experiment). Rapid 
and repeated emergence of SCVs occurred in independent bacterial 
populations, indicating that SCVs are an adaptive trait in the interac-
tion with this key immune cell (Dettman et al., 2012; Elena & Lenski, 
2003).
Here, we used whole- genome sequencing (WGS) of multiple clones 
to understand what is the genetic basis of SCVs and if the phenotypic 
parallelism is mediated by genetic parallelism. Our analysis shows evi-
dence of parallelism from the gene to the pathway level and indicates 
widespread functional parallelism: all SCVs had mutations in genes 
related to the ETC, a common observation in clinically isolated SCVs 
(Proctor et al., 1995; Roggenkamp et al., 1998). Importantly, we iden-
tified several mutational targets that had not previously been associ-
ated with SCVs, including nuoG, hemY or ubiG. As is often observed 
for ETC- deficient SCVs (Proctor et al., 2006), we show that these SCV 
clones generally have a high reversion rate, are hemin auxothrophs, 
and generally reach a lower carrying capacity than the ancestral strain, 
both in poor and rich media. As SCVs emerged in the presence of MΦs, 
and such morphotypes have previously been shown to have increased 
antibiotic resistance, we tested for SCV fitness inside MΦs and for 
antibiotic resistance in vitro and upon colonization of the mouse gut. 
Our results show that SCVs can have an intracellular advantage inside 
MΦs, and that this morphotype has a pattern of antagonistic pleiot-
ropy for antibiotic resistance in vitro: SCVs were more resistant to 
aminoglycosides but more sensitive to tetracycline, nalidixic acid and 
ciprofloxacin (quinolones), as well as cefotaxime (a β- lactam). Notably, 
upon colonization of streptomycin- treated mice, SCVs demonstrated 
a fitness advantage that could be increased upon kanamycin treat-
ment (an aminoglycoside) or decreased by nalidixic acid or tetracycline 
(as predicted by in vitro results), with tetracycline treatment strongly 
reducing SCV frequency in the mouse gut. Therefore, our results show 
that E. coli SCVs that emerge in the presence of MΦs are caused by 
mutations in a common pathway and have important pleiotropic con-
sequences for host- microbe interactions.
2  | MATERIAL AND METHODS
2.1 | Isolation of SCV clones, reference bacterial 
strains and MΦs
We isolated SCV clones from a previous experiment, in which 
E. coli was adapted to MΦs (see Appendix S1). These SCV clones 
were evolved from an ancestral strain of commensal E. coli (MC4100- 
CFP), which is streptomycin resistant (RpsLK43R) and constitutively 
expresses cyan- fluorescent protein (CFP; galK::CFP, AmpR). SCVs 
were identified in five of six independently evolving populations 
(Miskinyte et al., 2013; exception was population M4). Stocks of 
two randomly selected SCV clones (per population) were made 
and kept at −80°C. For population M4, two clones were also 
isolated. These clones produce colonies of similar size to the 
ancestral strain (see Fig. S1 for colony sizes) and were used as 
positive controls (i.e. clones that evolved with MΦs, but do not 
display a SCV phenotype) for the experiments below.
For competition assays, strain MC4100- YFP was used as reference 
strain. This differs from MC4100- CFP only in the expressed fluores-
cent protein. For the catalase activity test, a ΔrpoS strain was used as a 
negative control (Al Mamun et al., 2012). The RAW 264.7 murine MΦ 
cell line was used to test for SCV intracellular survival (see Appendix 
S1 for MΦ- culture conditions).
2.2 | Whole- genome sequencing and mutation 
prediction
Bacterial clones were grown in 10 ml RPMI at 37°C with 5% 
CO2. DNA was extracted using the procedure described by Wilson 
(2001). DNA library construction and sequencing was performed 
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by the IGC genomics facility. Each clone was paired- end sequenced 
on an Illumina MiSeq Benchtop- Sequencer. Standard procedures 
produced data sets of Illumina paired- end 250 bp read pairs, with 
mean coverage of 55× (32×–113× per clone). The genome sequenc-
ing data have been deposited in the NCBI Sequence Read Archive 
www.ncbi.nlm.nih.gov/sra (accession no.: SRP074322). breseq v0.20 
was used to map reads and identify mutations, using the E. coli 
BW2952 genome as reference (NCBI accession: NC_012759.1; 
Deatherage & Barrick, 2014). Default settings were used, except 
for eliminating mutation predictions occurring in homopolymers of 
length >3. Mutations were determined by comparison with the 
ancestral (MC4100- CFP; previously sequenced for (Miskinyte et al., 
2013). All predicted polymorphisms were manually inspected using 
IGV. Functional annotation clustering was performed using DAVID 
(Huang, Sherman, & Lempicki, 2008, 2009), with standard 
settings.
2.3 | Phenotypic traits of SCVs
Whole- genome sequencing revealed that SCVs had mutations in 
genes associated with the ETC. These SCVs often show the fol-
lowing phenotypes: (i) high reversion frequency to large colony 
phenotype; (ii) reduced catalase activity; (iii) slow growth in vitro; 
and (iv) auxotrophy for compounds involved in the ETC (Proctor 
et al., 2006). To test whether our SCVs had these phenotypes, 
we (i) measured reversion frequency (to large colony phenotype) 
and catalase activity as described in Miskinyte et al. (2013) and 
Roggenkamp et al. (1998) (see Appendix S1); (ii) estimated the 
relative growth rate and relative carrying capacity of each SCV 
(relative to the ancestral) in rich (RPMI) and poor media (M9 mini-
mal media with 0.4% glucose); and (iii) tested for auxotrophy to 
hemin and aminolevulinic acid (5- ALA) by estimating the lag phase, 
maximum growth rate and carrying capacity in the presence of 
these compounds relative to that obtained in its absence. Carrying 
capacity is defined as the maximum number of individuals (meas-
ured by OD) that can be supported by the environment (see 
Appendix S1 for further description of these assays).
2.4 | Bacterial survival inside MΦs
Three independently evolved clones carrying distinct mutations (28 
and 41 as SCVs and 31 as a positive control; see Table 1) were 
competed against the YFP ancestral strain in the intracellular envi-
ronment of MΦs. MΦs were seeded and activated, following a 
modification of Miskinyte & Gordo (2014) (see Appendix S1). On 
infection day, media were removed from each well and replaced 
by 1 ml RPMI with 107 bacteria, a ~50:50 mixture of the YFP 
ancestral and one of the evolved (CFP) clones (three wells per 
clone- time point combination). Cultures were spun down (200 g, 
5 min.) and plates incubated for 0.5 hr (37°C, 5% CO2). After this 
period, media were removed from all wells and cells washed twice 
with RPMI to remove extracellular bacteria. RPMI with gentamicin 
was added to two sets of wells (100 μg/ml), to kill remaining 
extracellular bacteria and plates incubated for another 0.5 hr (i.e. 
total incubation time = 1 hr) or 5.5 hr (i.e. total = 6 hr). About 
1 ml PBS was added to the remaining set of wells, and MΦs 
were detached and the contents of each well centrifuged to lyse 
MΦs (9400 g, 5 min). The pellet was then resuspended in 1 ml 
PBS. This allowed estimation of the number of bacteria that had 
been phagocytized by MΦs at 0.5 hr. At the 1 and 6 hr time-
points, MΦs were washed, detached and centrifuged, as for the 
0.5 hr timepoint. All timepoints were plated, and the number of 
YFP (ancestral) and CFP (SCVs) bacteria was used to calculate the 
competitive index (CI) as 
where xh represents 1- or 6- hr incubation, CFP (or YFP) represents 
the colony- forming units (cfu) at a particular time point. Six inde-
pendent replicates were performed, per clone. We used gentamicin, 
a standard antibiotic for bacterial intracellular survival assays, due 
to its reduced ability to enter cells and kill intracellular bacteria 
(Cano et al., 2003; Carryn, Van Bambeke, Mingeot- Leclercq, & 
Tulkens, 2002; Nguyen et al., 2009). To ensure that the observed 
fitness effects are due to environmental conditions inside MΦs 
and not because gentamicin increases SCV relative fitness, we 
carried out in vitro competitions in the absence of MΦs. These 
mimic the competitions with MΦs: 50:50 mixtures (107 bacteria) 
of each SCV clone and the YFP ancestral were inoculated into 
RPMI (1 ml), with gentamicin at 100 μg/ml, at pH 5 (mimicking 
the MΦ intracellular environment) or 7.4 (standard for RPMI). 
Cultures were incubated for 6 hr and then plated. In three inde-
pendent experiments (per SCV clone), SCV or ancestral colonies 
were only rarely observed, indicating that most bacteria (both SCVs 
and ancestral) cannot survive (Table S1). Moreover, we also carried 
competitions between isogenic CFP and YFP ancestral (Fig. S2) 
and observe that the CI was not significantly different from 0 at 
both 1 hr (t4 = 0.43, p = .69) and 6 hr (t4 = 1.47, p = .22), 
indicating that the fluorescent markers are neutral in this 
environment.
2.5 | In vitro antibiotic resistance assays
Antibiotic sensitivity was measured using disc diffusion assays (on 
LB- agar plates) for the following antibiotics: gentamicin (10 μg), 
kanamycin (30 μg), amikacin (30 μg), tobramycin (10 μg), netilmicin 
(10 μg), cefotaxime (30 μg), ciprofloxacin (5 μg), nalidixic acid 
(30 μg) and tetracycline (30 μg). The inhibition halo was measured 
48 hr postincubation, at 37°C (3–8 independent replicates per 
clone- antibiotic combination).
2.6 | In vivo competition assays in the mouse gut
To test the competitive ability of SCVs in vivo, we used the 
streptomycin- treated mouse model of E. coli colonization (Conway, 
Krogfelt, & Cohen, 2004). This model enables colonization by E. coli, 
(1)CI= log10
(
CFPxh
YFPxh
/
CFP0.5 hr
YFP0.5 hr
)
,
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while maintaining a diverse microbiota (Barroso- Batista, Demengeot, 
& Gordo, 2015). Briefly, 8- week- old C57BL/6 female mice raised 
in specific pathogen- free conditions (ad libitum food), were given 
autoclaved water with streptomycin (5 g/L) for 7 days before and 
after colonization (total = 14 days). Mice were caged in pairs and 
gavaged with a suspension of 108 bacteria (in 100 μl PBS; as in 
Barroso- Batista et al. (2014)), consisting of a mix of SCV- CFP and 
ancestral YFP (ancestral and SCV carry the streptomycin- resistance 
allele RpsLK43R; Trindade et al., 2009). The SCV population con-
tained a mixture of equal numbers of the following genetically 
distinct clones: 1, 19, 26, 28, 41, 48 and 51, which cover all the 
mutations observed in our experiment (see Table 1). Groups of 
TABLE  1 Mutations identified in E. coli clones evolved in the presence of MΦs. Deletions (Δ), transposition of insertion sequences (IS) or 
small nucleotide insertions (+) are shown at the specific position of each mutation, within the gene. For SNPs, the particular nucleotide and 
corresponding amino acid replacement change is indicated. The deletion in clone 1 includes both intergenic and coding regions, starting at an 
intergenic position and ending within the cydA coding region. Genomic positions are indicated relative to the GenBank reference: 
NC_012759.1.
Population Day Clone no. Position Gene Mutation Annotation Product
M1 8   1    673,439 mngB/
[cydA]
Intergenic (+844/−3) 
– coding (5/1,569 nt)
Δ6 bp cydA: cytochrome bd- I terminal 
oxidase, subunit I; mngB: 
alpha- mannosidase
M1 8 61    174,223 hemL A→C L220R (CTG→CGG) Glutamate- 1- semialdehyde 
aminotransferase
3,077,939 yqiJ Coding (562/630 nt) IS5 Predicted inner membrane 
protein
4,205,688 yjbS Coding (193/204 nt) IS1 Hypothetical protein
M2 4 11    174,688 hemL C→T G65D (GGC→GAC) Glutamate- 1- semialdehyde 
aminotransferase
M2 4 19    905,376 ycbU Coding (297/543 nt) IS2 Predicted fimbrial- like adhesin 
protein
2,223,615 ubiG Coding (222–231/723 nt) Δ10 bp Bifunctional 
3- demethylubiquinone- 8 
3- O- methyltransferase and 
2- octaprenyl- 6- hydroxyphenol 
methylase
M3 5 26    174,223 hemL A→C L220R (CTG→CGG) Glutamate- 1- semialdehyde 
aminotransferase
3,077,939 yqiJ Coding (562/630 nt) IS5 Predicted inner membrane 
protein
M3 5 28    174,223 hemL A→C L220R (CTG→CGG) Glutamate- 1- semialdehyde 
aminotransferase
3,077,939 yqiJ Coding (562/630 nt) IS5 Predicted inner membrane 
protein
4,205,688 yjbS Coding (193/204 nt) IS1 Hypothetical protein
M5 8 41 2,939,858 pepP Coding (153/1,326 nt) IS1 Proline aminopeptidase P II
M5 8 48 1,069,386 ndh C→T H52Y (CAC→TAC) NADH:ubiquinone oxidoreduc-
tase II
2,283,177 nuoG G→C Y272* (TAC→TAG) NADH:ubiquinone oxidoreduc-
tase I, chain G
M6 4 51 2,927,004 ygfZ Coding (522/981 nt) +GC Folate- binding protein
3,874,865 hemY T→A D237V (GAT→GTT) Predicted protoheme IX 
synthesis protein
M6 4 52 2,927,004 ygfZ Coding (522/981 nt) +GC Folate- binding protein
3,874,865 hemY T→A D237V (GAT→GTT) Predicted protoheme IX 
synthesis protein
M4 5 31 4,324,488 mscM C→G W547C 
(TGG→TGC)
Mechanosensitive channel of 
miniconductance, monomer
M4 5 40 4,324,488 mscM C→G W547C 
(TGG→TGC)
Mechanosensitive channel of 
miniconductance, monomer
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four mice (caged in pairs) were used for each experimental group. 
Specifically, one group did not receive any additional treatment 
(‘no treatment’ in Fig. 3) and the other three groups were gavaged 
(between days 1 and 6) with the following antibiotics: kanamycin 
(1 mg), tetracycline (0.5 mg) or nalidixic acid (2 mg). Doses were 
based on per kg doses administered to human adults.
Mice in different cages were inoculated with independently grown 
bacteria and on different days. After E. coli gavage, faecal samples 
were obtained daily, homogenized and plated (LB- agar) for estimat-
ing CFP (SCV or revertant) and YFP (ancestral) cfu. As a control, four 
mice were also gavaged with a mix of isogenic CFP/YFP ancestral. For 
these mice, the YFP/CFP ratio did not significantly change over time 
(χ2
1
 = 0.82, p = .36; Fig. S3), indicating that the fluorescent markers are 
neutral in this environment. Moreover, to ensure that the observed 
fitness effects are due to the environmental conditions in the gut and 
not because streptomycin increases the relative fitness of SCVs, in 
vitro competitions were carried, mimicking the in vivo competitions. 
This consisted of inoculating a 50:50 mixture of the SCV population 
and the YFP ancestral into RPMI at 100 μg/ml or 500 μg/ml of strep-
tomycin (n = 3 replicates per concentration). Twenty- four hours post-
incubation, the frequency of CFP/YFP bacteria was estimated, with 
SCVs always being deleterious (see Fig. S3D), in accordance with: (i) 
SCVs having a growth disadvantage in RPMI (Fig. S5); (ii) all clones 
being streptomycin resistant (RpsLK43R).
2.7 | Data analysis
All analyses were carried in R version 3.2.1, using t- tests, Wilcoxon 
tests, ANOVA or linear mixed- effects models (http://www.r-project.
org/). Where required, data were transformed to meet assumptions 
made by parametric statistics.
2.8 | Ethics statement
All experiments involving animals were approved by the Institutional 
Ethics Committee at the Instituto Gulbenkian de Ciência (project 
nr. A009/2010 with approval date 2010/10/15), following the 
Portuguese legislation (PORT 1005/92) which complies with the 
European Directive 86/609/EEC of the European Council.
3  | RESULTS AND DISCUSSION
3.1 | Novel genetic targets, associated with the ETC, 
mediate the SCV phenotype in E. coli
Whole- genome sequencing of 10 SCV clones evolved during inter-
actions with MΦs and revealed a total of 19 mutations, with 1–3 
mutations per clone (average: 1.9; Table 1). This is a large number 
of mutations, given that SCVs were isolated after only 60–120 
generations of adaptation to MΦs. Interestingly, in half the popula-
tions (M1, M2 and M5), SCVs have distinct haplotypes and have 
therefore emerged independently. Thus, while we have not 
estimated the full genetic diversity within populations, it is clear 
that SCVs can be a polymorphic subpopulation, with different 
beneficial haplotypes in competition (a phenomenon known as 
clonal interference; Sniegowski & Gerrish, 2010).
The mutations in SCVs affected 11 different genetic targets, all in 
coding regions. To the best of our knowledge, 10 of these have not 
been previously associated with the SCV phenotype. The exception is 
hemL, the most common genetic target in our experiment: mutated in 
three of five independent populations. hemL has also been associated 
with SCVs in S. enterica, for spontaneous resistance to antimicrobial 
peptides (Pranting & Andersson, 2010) and during adaptation to the 
intracellular environment of fibroblasts (Cano et al., 2003). Addition-
ally, we observed parallel mutations in two other genes (yqiJ and yjbS: 
mutated twice), and at the haplotype level with clones carrying muta-
tions in hemL, yqiJ and yjbS being isolated from two different popu-
lations (M1 and M3). Importantly, functional annotation clustering 
(Table S2) and literature review on the function of the mutated genes 
revealed widespread functional parallelism, as all clones had at least 
one mutated gene associated with the ETC. Therefore, our WGS data 
show evidence for parallel adaptation at multiple levels.
Mutations in genes of the ETC are often associated with SCVs, 
however the diversity of mutational targets that can give rise to such 
SCVs is poorly understood. Our results (Table S2) indicate that the 
observed mutations target three classes of processes: first, oxidative 
phosphorylation, through mutations in subunit I of cytochrome bd 
oxidase (cydA; Green, Kranz, Lorence, & Gennis, 1984) and in both 
NADH:ubiquinone oxidoreductase I and II (nuoG and ndh, respectively, 
Young & Wallace, 1976; Weidner et al., 1993); second, heme and 
Fe- S cluster synthesis through mutations in: (i) two enzymes that are 
involved in heme synthesis (hemL and hemY), which is a key prosthetic 
group in several enzymes of the ETC (e.g. cytochromes; Alefounder, 
Abell, & Battersby, 1988; Ilag, Jahn, Eggertsson, & Söll, 1991); (ii) ygfZ, 
which is thought to be involved in the synthesis/repair of Fe- S clus-
ters (present in enzymes as NADH:ubiquinone oxidoreductase I; Ote 
et al., 2006; Waller et al., 2010); and third, ubiquinone synthesis (the 
key electron acceptor for the ETC; Stroobant, Young, & Gibson, 1972), 
through mutations in an O- methyltransferase (ubiG) and in pepP. While 
the function of pepP (an aminopeptidase) is not directly related to ETC 
(Yoshimoto, Murayama, Honda, Tone, & Tsuru, 1988), transposition of 
an insertion sequence (IS) into pepP is known to have polar effects 
on ubiH activity (part of the same operon; Way, Sallustio, Magliozzo, 
& Goldberg, 1999). We confirmed this result in our SCV clone, by 
demonstrating that (i) ubiH expression was strongly reduced in the 
pepP mutant (clone 41; Fig. S4A) and (ii) that this mutant was unable 
to grow in minimal media supplemented with succinate or glycerol, but 
not glucose (Fig. S4B and Appendix S1; this was previously known for 
ubiH mutants; Gupta, Mat- Jan, Latifi, & Clark, 2000; Joyce et al., 2006). 
Importantly, revertant clones, derived from clone 41 (i.e. producing a 
large colony morphotype), were able to grow on succinate and glycerol 
(Fig. S4C). As ubiH is involved in ubiquinone synthesis (Young, Stroo-
bant, Macdonald, & Gibson, 1973), these data indicate that the SCV 
phenotype of the pepP mutant is also mediated by reduced activity of 
the ETC (rather than a direct effect of disrupting pepP function).
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The two positive control clones, which do not show an SCV phe-
notype, (i.e. form large colonies; Fig. S1), carry a single mutation in 
mscM, which encodes a mechanosensitive ion channel of minicon-
ductance. This is potentially important under hypo- osmotic shock 
(Edwards et al., 2012), but is not associated with the ETC. Therefore, 
these results generally suggest that the SCV phenotype that emerged 
during E. coli adaptation to MΦs is mediated by defects in the ETC, as 
has often been observed for SCVs isolated from experiments or clinical 
samples, across multiple species (Cano et al., 2003; Dean et al., 2014; 
Pranting & Andersson, 2010; Proctor et al., 2006; Roggenkamp et al., 
1998).
3.2 | E. coli SCVs have phenotypes similar to SCVs 
from clinical isolates
We measured several phenotypes that are typically observed in 
SCVs with mutations in the ETC (both in clinical and experimental 
isolates; results summarized in Table S3). We found that SCVs 
had a generally high (but variable) reversion frequency (to large 
colony phenotype), ranging from 10−2 to ~10−6. In eight of 10 
clones, the reversion frequency was >10−5, in line with previous 
observations (Häussler et al., 1999; Proctor et al., 2006; 
Roggenkamp et al., 1998; Trülzsch et al., 2003). When tested 
for catalase activity, four SCV clones were catalase negative 
(Proctor et al., 2006), all of which carried mutations in hemL 
(clones 11, 26, 28, 61; Table S3). This is in agreement with the 
fact that heme is a co- factor in both E. coli catalases (Schellhorn, 
1995).
Small- colony variants typically show poor growth under in vitro 
conditions, as a result of auxotrophy for specific compounds (Proc-
tor et al., 2006; Wei et al., 2011). In agreement, our SCVs generally 
reached a lower carrying capacity than the ancestral strain, both in 
poor (M9glu0.4) and rich media (RPMI; Table S3; Fig. S5). However, the 
effect of the SCV phenotype on growth rate was media- dependent. In 
poor media, the relative growth rate was generally lower (8/10 SCV 
clones), but in rich media, this was strongly dependent on the SCV 
clone. Thus, it is important to understand how the within- host envi-
ronment affects SCV growth in order to be able to predict the in vivo 
fitness of this morphotype (this could be done through indirect meth-
ods as in Barroso- Batista et al. 2015).
Two of the auxotrophies that are often observed in SCVs with 
mutations in the ETC are for hemin and aminolevulinic acid (5- ALA; 
Proctor et al., 2006; Pranting & Andersson, 2010). Accordingly, sup-
plementation of our SCV clones with either of these compounds 
improved their growth (Table S3; Fig. S6). However, while the benefit 
provided by hemin was observed across all clones and growth param-
eters (lag phase, maximum growth rate and carrying capacity), 5- ALA 
specifically shortened the lag phase of only five clones, four of which 
carry mutations in hemL (~50% reduction). This is consistent with 
the described role of hemL in converting glutamate- 1- semialdehyde 
to 5- ALA (Ilag et al., 1991), the first committed precursor of heme- 
biosynthesis, a key co- factor in several proteins of the ETC (Ilag et al., 
1991).
These results highlight the pleiotropic consequences of the SCV 
phenotype. Moreover, while SCVs show qualitative convergence for 
slow growth and high reversion frequency, the phenotypes are quan-
titatively variable across SCV clones. The only clones that can be qual-
itatively distinguished are the hemL mutants due to their 5- ALA auxo-
throphy and negative catalase test.
3.3 | SCVs have a fitness advantage in the 
intracellular environment of macrophages
As the SCVs used in this study emerged in the presence of MΦs, 
we carried out competition assays to test whether SCVs have a 
fitness advantage inside MΦs. Figure 1 shows that an SCV clone 
carrying mutations in hemL, yqiJ and yjbS had a fitness advantage 
(CI significantly different from 0) after both short (1 hr) and pro-
longed (6 hr) residence inside MΦs (at 1 hr: CI = 0.14 ± 0.06, 
mean ± 2 standard errors, t5 = 6.84, p < .01; at 6 hr: CI = 0.22 ± 0.08, 
t5 = 8.25, p < .001). A clone with an IS1 insertion in pepP dis-
played a transient fitness advantage, visible at 1 hr 
(CI = 0.08 ± 0.08, t5 = 2.9, p = .03), but not at 6 hr. As the 
ancestral strain of E. coli does not replicate inside MΦs (as most 
commensal strains; Koli, Sudan, Fitzgerald, Adhya, & Kar, 2011), 
the observed fitness advantage of these SCVs is likely mediated 
by an increased survival ability of SCVs inside MΦs. We also 
tested a clone with an mscM mutation that shows a colony size 
similar to the ancestral and observed no change in competitive 
ability. Overall, these data show that SCVs have increased intracel-
lular survival in MΦs, providing an explanation for their repeated 
emergence during experimental adaptation of E. coli to MΦs 
(Miskinyte et al., 2013). This is also in agreement with studies 
showing that SCVs can emerge and have a fitness advantage in 
F IGURE  1 SCVs have a fitness advantage inside MΦs. 
Competitive index (CI) for two SCV clones (28, 41) and a positive 
control clone (31), inside MΦs at 1 hr (left) and 6 hr (right) 
postinfection (YFP ancestral is used as reference). Dots represent 
the CI for each independent experiment (n = 6), and lines represent 
mean ± 2 standard errors (SE), across all experiments. Significant 
deviations from CI = 0 are denoted by *(p < .05) or **(p < .01, t- test). 
See Figure S2 for evidence of marker neutrality
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the intracellular milieu of nonprofessional phagocytes (Cano et al., 
2003; Tuchscherr et al., 2011; Vesga et al., 1996).
3.4 | SCVs present antagonistic pleiotropy for 
antibiotic resistance in vitro
A common phenotype of SCVs is increased resistance to aminogly-
coside antibiotics (von Eiff et al., 1997; Musher et al., 1977). However, 
much less is known about the antibiotic resistance profile of SCVs 
against nonaminoglycoside antibiotics (Cano et al., 2003; Pranting 
& Andersson, 2010). In Fig. 2, we show that E. coli SCVs were 
generally more resistant to aminoglycosides, but were more sus-
ceptible to tetracycline, nalidixic acid and ciprofloxacin (quinolones), 
and cefotaxime (a β- lactam). All SCV clones had significantly increased 
resistance to at least three aminoglycosides (relative to the ancestral), 
but also increased susceptibility to at least three nonaminoglycosides 
(p < .05 ANOVA contrasts; see Fig. S7 for mean ± 2SE). The posi-
tive control clones (mscM mutants), whose colony size is similar to 
the ancestral, do not show such a pattern.
Recent work, using in vitro experimental evolution of E. coli in 
the presence of aminoglycosides, has shown that resistant mutants 
often have increased sensitivity to other antibiotics (including nalidixic 
acid, ciprofloxacin or tetracycline; Imamovic & Sommer, 2013; Lázár 
et al., 2013; Oz et al., 2014; Suzuki, Horinouchi, & Furusawa, 2014), a 
phenomenon termed collateral sensitivity (Szybalski & Bryson, 1952). 
Interestingly, some of these studies recurrently observed mutations in 
genes with similar functions to those observed here (e.g. heme synthe-
sis: hemA; NADH dehydrogenase I: nuoF and cytochrome bd- I terminal 
oxidase: cydA; Lázár et al., 2013; Oz et al., 2014; Suzuki et al., 2014), 
suggesting that adaptation to aminoglycosides may also lead to bacte-
ria that are more adapted to macrophages (Durão, Güleresi, Proença, 
& Gordo, in press; Miskinyte & Gordo, 2013).
3.5 | SCVs have a fitness advantage in vivo that can 
be reversed with tetracycline treatment
While several recent papers have shown collateral sensitivity in 
vitro (Imamovic & Sommer, 2013; Lázár et al., 2013; Roemhild, 
Barbosa, Beardmore, Jansen, & Schulenburg, 2015), whether this 
phenomenon also occurs in vivo is currently unknown. As the 
effect of resistance mutations is highly dependent on the environ-
ment (Miskinyte & Gordo, 2013; Trindade, Sousa, & Gordo, 2012), 
it is imperative to determine whether collateral sensitivity is also 
observed in vivo. Here, we used the streptomycin- treated mouse 
model of gut colonization to test for the competitive ability of 
SCVs against the ancestral, in the presence or absence of treat-
ment with kanamycin, nalidixic acid or tetracycline.
Remarkably, we observed that SCVs had a fitness advantage 
in the mouse gut (Fig. 3A,B): SCV frequency increased, and by day 
7, SCVs constituted the majority of the population in three of four 
mice. Accordingly, SCV ratio significantly increased with time (Fig. 3A; 
χ
2
1
 = 11.4, p < .001), with a positive selection coefficient (per day) of 
0.14 (±0.05, standard error; SE; see methods; (Dykhuizen, 1990); see 
Fig. S3 for slopes). Conversely, the frequency of revertant bacteria 
(forming large CFP colonies) decreased from ~0.12 on day 0 to below 
0.03 by day 7 post-colonization (Fig. 3B). These results show that 
SCVs can have an increased competitive ability in a natural environ-
ment for E. coli. Interestingly, E. coli SCVs have been isolated from the 
gut in natural infections of humans (Trülzsch et al., 2003) and during 
adaptation to the mouse gut (Lee et al., 2010).
In agreement with the in vitro results, SCV fitness in the mouse 
gut was dependent on the antibiotic treatment (time:treatment inter-
action: χ2
3
 = 58.9, p < .0001). SCV fitness significantly increased with 
kanamycin treatment (χ2
1
 = 10.2, p < .01), leading to a selection coef-
ficient of 0.36 (±0.05, SE). On the other hand, tetracycline treatment, 
F IGURE  2 SCVs show increased resistance to aminoglycosides, but collateral sensitivity to other antibiotic classes. Heatmap of the relative 
inhibition halo (i.e. mean inhibition halo for SCV clones relative to that of the ancestral). In total, 3–8 independent replicates were carried for 
any clone- antibiotic combination. Colours red, blue and white indicate whether the inhibition halo is smaller (i.e. more resistant), larger (i.e. more 
sensitive) or equal to the ancestral, respectively. Significant differences (p < .05; anova contrasts) relative to the ancestral are denoted by a “*”. 
AMI – Amikacin; GEN – Gentamicin; KAN – Kanamycin; NET – Netilmicin; TOB – Tobramycin; TET – Tetracycline; NAL – Nalidixic acid; CIP – 
Ciprofloxacin; CTX – Cefotaxime. See Fig. S7 for the mean (±2SE) relative inhibition halo and the mean halo (in mm)
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significantly reduced SCV fitness within the mouse gut (χ2
1
 = 28.8, 
p < .0001), leading to a fitness disadvantage (selection coefficient: 
−0.23 ± 0.05, SE). Nalidixic acid also led to a reduction in the fitness 
advantage of SCVs (slope: 0.05 ± 0.05, SE). However, this difference 
was not significant (χ2
1
 = 1.9, p = .17).
As far as we are aware, these results provide the first in vivo 
demonstration that the frequency of SCVs can be increased by 
aminoglycoside treatment, but decreased by tetracycline due to their 
collateral sensitivity to this antibiotic. Furthermore, while we observed 
that antibiotics strongly influence the composition of the E. coli popu-
lation, the total population size remains relatively stable (Fig. S3), albeit 
lower than in mice drinking only streptomycin- treated water (χ2
1
 = 4.8, 
p = .03). As commensal bacteria can acquire pathogenic traits through 
just a few mutations (Koli et al., 2011; Limoli et al., 2014; Miskinyte 
F IGURE  3 The fitness advantage of SCVs within the mouse gut is modulated by antibiotic treatment. (A and C) Boxplots of the competitive 
index (CI) of SCVs (CFP) against the ancestral (YFP), during colonization of the mouse gut in mice that did not received antibiotic treatment  
(A) or in mice that were treated (C) with kanamycin (left), nalidixic acid (centre) or tetracycline (right). CI was calculated as the natural logarithm 
of the ratio of CFP cfu to YFP cfu. (B and D) Frequency of fluorescent marker/colony size for mice without (B) or with (D) antibiotic treatment. 
Each panel represents a single mouse and shows the frequency of SCVs (SCV:CFP; dark blue), SCV revertants (REV:CFP; light blue) and ancestral 
bacteria (Anc:YFP; yellow). Horizontal dashed lines in A–D indicate where SCVs and Anc are competitively equivalent. See Fig. S3 for slopes of 
CI against time, mean (±2SE) CFP frequency and bacterial loads
(A) (C)
(B) (D)
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et al., 2013), these results suggest that it may be possible to reduce the 
frequency of bacteria with such traits (e.g. SCVs) without eliminating 
the commensals.
4  | CONCLUSIONS
Small- colony variants are an important bacterial morphotype often 
associated with chronic infections and antibiotic resistance. In this 
manuscript, we identified new mutational paths that confer an 
SCV phenotype and show that these mutations have multiple 
pleiotropic phenotypic consequences in vitro and in vivo (in the 
mouse gut). Thus, our results highlight that combining experimental 
evolution in the presence of key cells of the innate immune sys-
tem, with WGS and phenotypic tests can reveal: (i) the genetic 
basis of bacterial traits important for within- host fitness and (ii) 
the selective pressures that lead to such traits.
Importantly, the SCV phenotype leads to a trade- off, both in vitro 
and in vivo, between increased aminoglycoside resistance and collat-
eral sensitivity to other antibiotic classes. As SCVs carry multiple muta-
tions in genes related to the ETC, collateral sensitivity is likely mediated 
by a reduction in proton- motive force (PMF) across the inner mem-
brane. This is because resistance to other antibiotic classes is mediated 
by several PMF- dependent efflux pumps, thus reduced PMF can lead 
to increased sensitivity to some antibiotics (Lázár et al., 2013).
Collateral sensitivity has been suggested as an important principle 
for the design of treatment regimens that curb the evolution of antibi-
otic resistance (Imamovic & Sommer, 2013; Lázár et al., 2013). How-
ever, at the moment, we are aware of only a single report using this 
concept to treat bacteria in vivo (Gonzales et al., 2015). Thus, more 
work is currently needed to establish the in vivo effectiveness of ther-
apies involving collateral sensitivity (Baym, Stone, & Kishony, 2016).
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